Literature DB >> 7736920

Role of aldehyde oxidase in the in vitro conversion of famciclovir to penciclovir in human liver.

S E Clarke1, A W Harrell, R J Chenery.   

Abstract

Famciclovir is the diacetyl 6-deoxy derivative of the active antiviral penciclovir that is for use in the treatment of infections caused by the herpes family of viruses. The major pathway of conversion is via di-deacetylation to BRL 42359, followed by oxidation to penciclovir. On oral dosing of famciclovir to humans, only penciclovir and BRL 42359 can be detected consistently in the plasma; thus, attention was focused on the oxidation reaction. This 6-oxidation occurred rapidly in human liver cytosol, had no requirement for cofactors, and followed simple Michaelis-Menten kinetics with a KM of 115 microM +/- 23 (N = 3). Using inhibitors of xanthine oxidase (allopurinol) and aldehyde oxidase (menadione and isovanillin), the relative roles of these enzymes in this process were determined. At a concentration of BRL 42359 that reflected plasma concentrations observed in humans (4 microM), both menadione (IC50 7 microM) and isovanillin (IC50 15 microM) caused extensive inhibition of the 6-oxidation reaction. In contrast, allopurinol caused no significant inhibition, confirming earlier in vivo work. At higher substrate concentrations (50 and 200 microM), the results with these inhibitors were broadly similar. These results provide strong evidence that aldehyde oxidase and not xanthine oxidase is responsible for the 6-oxidation of BRL 42359 to penciclovir in human liver cytosol, and this is likely to reflect the in vivo situation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7736920

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  14 in total

1.  Inhibition of human liver aldehyde oxidase: implications for potential drug-drug interactions.

Authors:  John T Barr; Jeffrey P Jones
Journal:  Drug Metab Dispos       Date:  2011-09-22       Impact factor: 3.922

Review 2.  Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management.

Authors:  Jocelyne Piret; Guy Boivin
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

3.  Monitoring in vivo metabolism and elimination of the endogenous DNA adduct, M1dG {3-(2-deoxy-beta-D-erythro-pentofuranosyl)pyrimido[1,2-alpha]purin-10(3H)-one}, by accelerator mass spectrometry.

Authors:  Charles G Knutson; Paul L Skipper; Rosa G Liberman; Steven R Tannenbaum; Lawrence J Marnett
Journal:  Chem Res Toxicol       Date:  2008-05-08       Impact factor: 3.739

Review 4.  The role of non-P450 enzymes in drug oxidation.

Authors:  C Beedham
Journal:  Pharm World Sci       Date:  1997-12

Review 5.  Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions.

Authors:  R J Bertz; G R Granneman
Journal:  Clin Pharmacokinet       Date:  1997-03       Impact factor: 6.447

Review 6.  The clinical pharmacokinetics of famciclovir.

Authors:  K S Gill; M J Wood
Journal:  Clin Pharmacokinet       Date:  1996-07       Impact factor: 6.447

Review 7.  A review of antiviral drugs and other compounds with activity against feline herpesvirus type 1.

Authors:  Sara M Thomasy; David J Maggs
Journal:  Vet Ophthalmol       Date:  2016-04-19       Impact factor: 1.644

8.  Molybdenum and Tungsten Cofactors and the Reactions They Catalyze.

Authors:  Martin L Kirk; Khadanand Kc
Journal:  Met Ions Life Sci       Date:  2020-03-23

9.  Enzyme Kinetics, Pharmacokinetics, and Inhibition of Aldehyde Oxidase.

Authors:  Erickson M Paragas; Kanika Choughule; Jeffrey P Jones; John T Barr
Journal:  Methods Mol Biol       Date:  2021

10.  Antiviral Drugs Against Herpesviruses.

Authors:  Jocelyne Piret; Guy Boivin
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.